

## Appendix 13 - CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Approved settings/ treatment line	Chemotherapy protocols	Drugs in abbreviation	Evidence Category
1st line CLL with del(17p)/ TP53 mutation	Ibrutinib		Category 2A, Preferred
	Venetoclax + Obinutuzumab		Category 2A, Preferred
	Alemtuzumab ± Rituximab		Category 2A
	Obinutuzumab		Category 2A
	HD MethylPrednisolone + Rituximab		Category 2A
1st line CLL with	Ibrutinib		Category 2A, Preferred
del(17p)/ TP53	Venetoclax + Obinutuzumab		Category 2A, Preferred
mutation	Alemtuzumab ± Rituximab		Category 2A
> > > > > > > > > > > > > > > > > > > >	Obinutuzumab		Category 2A
	HD MethylPrednisolone + Rituximab		Category 2A
1st line CLL without	Ibrutinib		Category 1, Preferred
del(17p)/ TP53	Venetoclax + Obinutuzumab		Category 2A, Preferred
mutation for	Bendamustine + Rituximab		Category 2A
patients with comorbidities*	Bendamustine + Obinutuzumab		Category 2A
Comorbiantes	Chlorambucil + Obinutuzumab		Category 2A
	HD MethylPrednisolone + Rituximab		Category 2B
	Ibrutinib + Obinutuzumab		Category 2B
	Obinutuzumab		Category 2B
	Chlorambucil		Category 3
<u> </u>	Rituximab		Category 3
1st line CLL without del(17p)/ TP53	Ibrutinib		Category 1, Preferred
	Venetoclax + Obinutuzumab		Category 2A, Preferred
mutation for	Bendamustine + Rituximab		Category 2A
patients without comorbidities*	Bendamustine + Obinutuzumab		Category 2A
comorbidities	ECD	Fludarabine, Cyclophosphamide,	Catalana 2A
	FCR	Rituximab	Category 2A
	FR Silver I	Fludarabine, Rituximab	Category 2A
	HD MethylPrednisolone + Rituximab		Category 2B
200	Ibrutinib + Rituximab		Category 2B
Maintenance therapy CLL without del(17p)/ TP53 mutation**	Lenalidomide		Category 2A



	Chemotherapy protocols	Drugs in abbreviation	Evidence Category
			Category 1,
Relapsed/ refractory CLL without del(17p)/ TP53 mutation for patients with comorbidities*	Ibrutinib		Preferred
			Category 1,
	Venetoclax + Rituximab		Preferred
	Alemtuzumab ± Rituximab		Category 2A
	Chlorambucil + Rituximab		Category 2A
		Fludarabine,	
		Cyclophosphamide,	
	Reduced dose FCR	Rituximab	Category 2A
	HD MethylPrednisolone +		
	Rituximab		Category 2A
	Lenalidomide ± Rituximab		Category 2A
	Obinutuzumab		Category 2A
	Ofatumumab		Category 2A
	Venetoclax		Category 2A
	Dose-dense Rituximab		Category 2B
	Bendamustine + Rituximab ±		
	Ibrutinib		Category 2B
			Category 1,
	Ibrutinib		Preferred
Dolomood/sofwortows Cl			Category 1,
	Venetoclax + Rituximab		Preferred
	Alemtuzumab ± Rituximab		Category 2A
Relapsed/ refractory CLL without del(17p)/ TP53	Bendamustine + Rituximab		Category 2A
mutation for patients		Fludarabine,	
without comorbidities*	FC + Obinutuzumab	Cyclophosphamide	Category 2A
		Fludarabine,	
		Cyclophosphamide,	
	FCR	Rituximab	Category 2A
	HD MethylPrednisolone +		
	Rituximab		Category 2A
	Lenalidomide ± Rituximab		Category 2A
	Obinutuzumab		Category 2A
	Ofatumumab		Category 2A
	Venetoclax		Category 2A
	Bendamustine + Rituximab +		
	Ibrutinib		Category 2B
Post 2nd line maintenance	Lenalidomide		Category 2A
therapy CLL without			
del(17p)/ TP53 mutation	Ofeline		Catalana 25
	Ofatumumab nalogues, Age ≥ 65 years, CrCl < 70 m		Category 2B

<sup>\*\*</sup> Blood MRD ≥ 10-2 or ≥ 10-4 and < 10-2 with unmutated IGHV after 1st line therapy